ID   PK3CA_HUMAN             Reviewed;        1068 AA.
AC   P42336; Q14CW1; Q99762;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   21-MAR-2012, entry version 128.
DE   RecName: Full=Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;
DE            Short=PI3-kinase subunit alpha;
DE            Short=PI3K-alpha;
DE            Short=PI3Kalpha;
DE            Short=PtdIns-3-kinase subunit alpha;
DE            EC=2.7.1.153;
DE   AltName: Full=Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;
DE            Short=PtdIns-3-kinase subunit p110-alpha;
DE            Short=p110alpha;
DE   AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide;
DE   AltName: Full=Serine/threonine protein kinase PIK3CA;
DE            EC=2.7.11.1;
GN   Name=PIK3CA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-43 AND ARG-332.
RX   MEDLINE=95229146; PubMed=7713498; DOI=10.1006/geno.1994.1655;
RA   Volinia S., Hiles I., Ormondroyd E., Nizetic D., Antonacci R.,
RA   Rocchi M., Waterfield M.;
RT   "Molecular cloning, cDNA sequence, and chromosomal localization of the
RT   human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene.";
RL   Genomics 24:472-477(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=97196568; PubMed=9043658; DOI=10.1016/S0968-0896(96)00196-4;
RA   Stirdivant S.M., Ahern J., Conroy R.R., Barnett S.F., Ledder L.M.,
RA   Oliff A., Heimbrook D.C.;
RT   "Cloning and mutagenesis of the p110 alpha subunit of human
RT   phosphoinositide 3'-hydroxykinase.";
RL   Bioorg. Med. Chem. 5:65-74(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH APPL1.
RX   MEDLINE=99422021; PubMed=10490823; DOI=10.1038/sj.onc.1203080;
RA   Mitsuuchi Y., Johnson S.W., Sonoda G., Tanno S., Golemis E.A.,
RA   Testa J.R.;
RT   "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an
RT   adaptor molecule that interacts with the oncoprotein-serine/threonine
RT   kinase AKT2.";
RL   Oncogene 18:4891-4898(1999).
RN   [5]
RP   FUNCTION IN INVADOPODIA FORMATION, AND CHARACTERIZATION OF VARIANTS
RP   LYS-545 AND ARG-1047.
RX   PubMed=21708979; DOI=10.1083/jcb.201009126;
RA   Yamaguchi H., Yoshida S., Muroi E., Yoshida N., Kawamura M.,
RA   Kouchi Z., Nakamura Y., Sakai R., Fukami K.;
RT   "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha}
RT   regulates invadopodia formation.";
RL   J. Cell Biol. 193:1275-1288(2011).
RN   [6]
RP   REVIEW ON CANCER.
RX   PubMed=18418043;
RA   Huang C.-H., Mandelker D., Gabelli S.B., Amzel L.M.;
RT   "Insights into the oncogenic effects of PIK3CA mutations from the
RT   structure of p110alpha/p85alpha.";
RL   Cell Cycle 7:1151-1156(2008).
RN   [7]
RP   REVIEW ON FUNCTION, AND REVIEW ON CANCER.
RX   PubMed=18794883; DOI=10.1038/onc.2008.244;
RA   Zhao L., Vogt P.K.;
RT   "Class I PI3K in oncogenic cellular transformation.";
RL   Oncogene 27:5486-5496(2008).
RN   [8]
RP   REVIEW ON FUNCTION.
RX   PubMed=19200708; DOI=10.1016/j.ceb.2008.12.007;
RA   Jia S., Roberts T.M., Zhao J.J.;
RT   "Should individual PI3 kinase isoforms be targeted in cancer?";
RL   Curr. Opin. Cell Biol. 21:199-208(2009).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1, AND
RP   DOMAINS.
RX   PubMed=18079394; DOI=10.1126/science.1150799;
RA   Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y.,
RA   Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B.,
RA   Amzel L.M.;
RT   "The structure of a human p110alpha/p85alpha complex elucidates the
RT   effects of oncogenic PI3Kalpha mutations.";
RL   Science 318:1744-1748(2007).
RN   [10]
RP   STRUCTURE BY NMR OF 331-481.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C2 domain from human PI3-kinase p110
RT   subunit alpha.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX
RP   WITH WORTMANNIN AND PIK3R1, INTERACTION WITH PIK3R1, CHARACTERIZATION
RP   OF VARIANT ARG-1047, AND DOMAINS.
RX   PubMed=19805105; DOI=10.1073/pnas.0908444106;
RA   Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I.,
RA   Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.;
RT   "A frequent kinase domain mutation that changes the interaction
RT   between PI3Kalpha and the membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009).
RN   [12]
RP   VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047;
RP   LEU-1047 AND TYR-1065.
RX   PubMed=15289301; DOI=10.1158/0008-5472.CAN-04-1170;
RA   Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M.,
RA   McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., Yan H.;
RT   "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade
RT   astrocytomas, and medulloblastomas.";
RL   Cancer Res. 64:5048-5050(2004).
RN   [13]
RP   VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; ARG-1047 AND
RP   LEU-1047.
RX   PubMed=15520168; DOI=10.1158/0008-5472.CAN-04-2933;
RA   Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G.,
RA   Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B.,
RA   Phillips W.A.;
RT   "Mutation of the PIK3CA gene in ovarian and breast cancer.";
RL   Cancer Res. 64:7678-7681(2004).
RN   [14]
RP   VARIANT CANCER ARG-1047.
RX   PubMed=15016963; DOI=10.1126/science.1096502;
RA   Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S.,
RA   Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K.V.,
RA   Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E.;
RT   "High frequency of mutations of the PIK3CA gene in human cancers.";
RL   Science 304:554-554(2004).
RN   [15]
RP   VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025.
RX   PubMed=15924253; DOI=10.1007/s00401-005-1000-1;
RA   Hartmann C., Bartels G., Gehlhaar C., Holtkamp N., von Deimling A.;
RT   "PIK3CA mutations in glioblastoma multiforme.";
RL   Acta Neuropathol. 109:639-642(2005).
RN   [16]
RP   VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047.
RX   PubMed=15784156; DOI=10.1186/1471-2407-5-29;
RA   Li V.S.W., Wong C.W., Chan T.L., Chan A.S.W., Zhao W., Chu K.-M.,
RA   So S., Chen X., Yuen S.T., Leung S.Y.;
RT   "Mutations of PIK3CA in gastric adenocarcinoma.";
RL   BMC Cancer 5:29-29(2005).
RN   [17]
RP   CHARACTERIZATION OF VARIANTS CANCER HIS-38; VAL-106; ARG-420; GLN-453;
RP   LYS-542; LYS-545; ILE-1043 AND ARG-1047.
RX   PubMed=15930273; DOI=10.1158/0008-5472.CAN-04-4114;
RA   Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J.,
RA   Ohta M., Jazag A., Guleng B., Tateishi K., Asaoka Y., Matsumura M.,
RA   Kawabe T., Omata M.;
RT   "Functional analysis of PIK3CA gene mutations in human colorectal
RT   cancer.";
RL   Cancer Res. 65:4562-4567(2005).
RN   [18]
RP   VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007;
RP   HIS-1021; CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050;
RP   LYS-1052 AND LEU-1065.
RX   PubMed=16322209; DOI=10.1158/0008-5472.CAN-05-2620;
RA   Oda K., Stokoe D., Taketani Y., McCormick F.;
RT   "High frequency of coexistent mutations of PIK3CA and PTEN genes in
RT   endometrial carcinoma.";
RL   Cancer Res. 65:10669-10673(2005).
RN   [19]
RP   VARIANTS CANCER LYS-542; GLY-545; LYS-545; GLN-1023; ARG-1047 AND
RP   LEU-1047.
RX   PubMed=15994075; DOI=10.1016/j.ejca.2005.04.022;
RA   Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G.,
RA   Schwartz S. Jr., Duval A., Carneiro F., Machado J.C., Hamelin R.,
RA   Seruca R.;
RT   "The prevalence of PIK3CA mutations in gastric and colon cancer.";
RL   Eur. J. Cancer 41:1649-1654(2005).
RN   [20]
RP   VARIANTS CANCER LYS-545 AND ARG-1047.
RX   PubMed=15712344; DOI=10.1002/humu.9316;
RA   Wang Y., Helland A., Holm R., Kristensen G.B., Boerresen-Dale A.-L.;
RT   "PIK3CA mutations in advanced ovarian carcinomas.";
RL   Hum. Mutat. 25:322-322(2005).
RN   [21]
RP   VARIANT HCC ALA-545.
RX   PubMed=15608678; DOI=10.1038/sj.onc.1208304;
RA   Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W.,
RA   Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.;
RT   "PIK3CA gene is frequently mutated in breast carcinomas and
RT   hepatocellular carcinomas.";
RL   Oncogene 24:1477-1480(2005).
RN   [22]
RP   VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047, AND VARIANT
RP   MET-391.
RX   PubMed=16533766; DOI=10.1158/1078-0432.CCR-05-2173;
RA   Qiu W., Schoenleben F., Li X., Ho D.J., Close L.G., Manolidis S.,
RA   Bennett B.P., Su G.H.;
RT   "PIK3CA mutations in head and neck squamous cell carcinoma.";
RL   Clin. Cancer Res. 12:1441-1446(2006).
RN   [23]
RP   VARIANT CANCER ARG-1047.
RX   PubMed=16114017; DOI=10.1002/ijc.21444;
RA   Or Y.Y.-Y., Hui A.B.-Y., To K.-F., Lam C.N.-Y., Lo K.-W.;
RT   "PIK3CA mutations in nasopharyngeal carcinoma.";
RL   Int. J. Cancer 118:1065-1067(2006).
RN   [24]
RP   VARIANTS CANCER LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND
RP   LEU-1047.
RX   PubMed=16353168; DOI=10.1002/path.1908;
RA   Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D.,
RA   Fresu G., Salvatore S., Cuccurullo F., Mezzetti A., Campani D.,
RA   Marchetti A.;
RT   "PIK3CA mutation and histological type in breast carcinoma: high
RT   frequency of mutations in lobular carcinoma.";
RL   J. Pathol. 208:350-355(2006).
RN   [25]
RP   CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047.
RX   PubMed=16432179; DOI=10.1073/pnas.0510857103;
RA   Bader A.G., Kang S., Vogt P.K.;
RT   "Cancer-specific mutations in PIK3CA are oncogenic in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:1475-1479(2006).
RN   [26]
RP   VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047.
RX   PubMed=17673550; DOI=10.1073/pnas.0705218104;
RA   Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E.,
RA   Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R.,
RA   Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A.,
RA   Real F.X.;
RT   "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic
RT   keratoses with a characteristic mutation pattern.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:13450-13454(2007).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) that phosphorylates
CC       PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-
CC       phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-
CC       bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate
CC       (PIP3). PIP3 plays a key role by recruiting PH domain-containing
CC       proteins to the membrane, including AKT1 and PDPK1, activating
CC       signaling cascades involved in cell growth, survival,
CC       proliferation, motility and morphology. Participates in cellular
CC       signaling in response to various growth factors. Involved in the
CC       activation of AKT1 upon stimulation by receptor tyrosine kinases
CC       ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in
CC       signaling via insulin-receptor substrate (IRS) proteins. Essential
CC       in endothelial cell migration during vascular development through
CC       VEGFA signaling, possibly by regulating RhoA activity. Required
CC       for lymphatic vasculature development, possibly by binding to RAS
CC       and by activation by EGF and FGF2, but not by PDGF. Regulates
CC       invadopodia formation in breast cancer cells through the PDPK1-
CC       AKT1 pathway. Participates in cardiomyogenesis in embryonic stem
CC       cells through a AKT1 pathway. Participates in vasculogenesis in
CC       embryonic stem cells through PDK1 and protein kinase C pathway.
CC       Has also serine-protein kinase activity: phosphorylates PIK3R1
CC       (p85alpha regulatory subunit), EIF4EBP1 and HRAS.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       trisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85
CC       regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1
CC       in nuclear extracts. Interacts with RUFY3 (By similarity).
CC       Interacts with RASD2 (By similarity). Interacts with APPL1.
CC       Interacts with HRAS1 and KRAS (By similarity). Interaction with
CC       HRAS1/KRAS is required for PI3K pathway signaling and cell
CC       proliferation stimulated by EGF and FGF2 (By similarity).
CC   -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with
CC       the PI3K/PI4K kinase domain. The C2 PI3K-type domain may
CC       facilitate the recruitment to the plasma membrane. The inhibitory
CC       interactions with PIK3R1 are mediated by the PI3K-ABD domain and
CC       the C2 PI3K-type domain with the iSH2 (inter-SH2) region of
CC       PIK3R1, and the C2 PI3K-type domain, the PI3K helical domain, and
CC       the PI3K/PI4K kinase domain with the nSH2 (N-terminal SH2) region
CC       of PIK3R1.
CC   -!- DISEASE: Note=Most of the cancer-derived mutations are missense
CC       mutations and map to one of the three hotspots: Glu-542; Glu-545
CC       and His-1047. Mutated isoforms participate in cellular
CC       transformation and tumorigenesis induced by oncogenic receptor
CC       tyrosine kinases (RTKs) and HRAS1/KRAS. Interaction with
CC       HRAS1/KRAS is required for Ras-driven tumor formation. Mutations
CC       increasing the lipid kinase activity are required for oncogenic
CC       signaling. The protein kinase activity may not be required for
CC       tumorigenesis.
CC   -!- DISEASE: Defects in PIK3CA are associated with colorectal cancer
CC       (CRC) [MIM:114500].
CC   -!- DISEASE: Defects in PIK3CA are a cause of susceptibility to breast
CC       cancer (BC) [MIM:114480]. A common malignancy originating from
CC       breast epithelial tissue. Breast neoplasms can be distinguished by
CC       their histologic pattern. Invasive ductal carcinoma is by far the
CC       most common type. Breast cancer is etiologically and genetically
CC       heterogeneous. Important genetic factors have been indicated by
CC       familial occurrence and bilateral involvement. Mutations at more
CC       than one locus can be involved in different families or even in
CC       the same case.
CC   -!- DISEASE: Defects in PIK3CA are a cause of susceptibility to
CC       ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy
CC       originating from ovarian tissue. Although many histologic types of
CC       ovarian neoplasms have been described, epithelial ovarian
CC       carcinoma is the most common form. Ovarian cancers are often
CC       asymptomatic and the recognized signs and symptoms, even of late-
CC       stage disease, are vague. Consequently, most patients are
CC       diagnosed with advanced disease.
CC   -!- DISEASE: Defects in PIK3CA may underlie hepatocellular carcinoma
CC       (HCC) [MIM:114550].
CC   -!- DISEASE: Defects in PIK3CA are a cause of keratosis seborrheic
CC       (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic
CC       keratoses usually begin with the appearance of one or more sharply
CC       defined, light brown, flat macules. The lesions may be sparse or
CC       numerous. As they initially grow, they develop a velvety to finely
CC       verrucous surface, followed by an uneven warty surface with
CC       multiple plugged follicles and a dull or lackluster appearance.
CC   -!- MISCELLANEOUS: The avian sarcoma virus 16 genome encodes an
CC       oncogene derived from PIK3CA (PubMed:18418043).
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC   -!- SIMILARITY: Contains 1 C2 PI3K-type domain.
CC   -!- SIMILARITY: Contains 1 PI3K-ABD domain.
CC   -!- SIMILARITY: Contains 1 PI3K-RBD domain.
CC   -!- SIMILARITY: Contains 1 PI3K/PI4K domain.
CC   -!- SIMILARITY: Contains 1 PIK helical domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z29090; CAA82333.1; -; mRNA.
DR   EMBL; U79143; AAB39753.1; -; mRNA.
DR   EMBL; BC113601; AAI13602.1; -; mRNA.
DR   EMBL; BC113603; AAI13604.1; -; mRNA.
DR   IPI; IPI00031386; -.
DR   PIR; I38110; I38110.
DR   RefSeq; NP_006209.2; NM_006218.2.
DR   UniGene; Hs.553498; -.
DR   UniGene; Hs.85701; -.
DR   PDB; 2ENQ; NMR; -; A=331-481.
DR   PDB; 2RD0; X-ray; 3.05 A; A=1-1068.
DR   PDB; 3HHM; X-ray; 2.80 A; A=1-1068.
DR   PDB; 3HIZ; X-ray; 3.30 A; A=1-1068.
DR   PDBsum; 2ENQ; -.
DR   PDBsum; 2RD0; -.
DR   PDBsum; 3HHM; -.
DR   PDBsum; 3HIZ; -.
DR   ProteinModelPortal; P42336; -.
DR   SMR; P42336; 16-105, 333-481.
DR   DIP; DIP-42728N; -.
DR   IntAct; P42336; 16.
DR   MINT; MINT-1367228; -.
DR   STRING; P42336; -.
DR   PhosphoSite; P42336; -.
DR   DMDM; 126302584; -.
DR   PRIDE; P42336; -.
DR   DNASU; 5290; -.
DR   Ensembl; ENST00000263967; ENSP00000263967; ENSG00000121879.
DR   GeneID; 5290; -.
DR   KEGG; hsa:5290; -.
DR   UCSC; uc003fjk.1; human.
DR   CTD; 5290; -.
DR   GeneCards; GC03P178865; -.
DR   H-InvDB; HIX0030866; -.
DR   HGNC; HGNC:8975; PIK3CA.
DR   HPA; CAB017804; -.
DR   HPA; HPA009985; -.
DR   MIM; 114480; phenotype.
DR   MIM; 114500; phenotype.
DR   MIM; 114550; phenotype.
DR   MIM; 167000; phenotype.
DR   MIM; 171834; gene.
DR   MIM; 182000; phenotype.
DR   neXtProt; NX_P42336; -.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   PharmGKB; PA33308; -.
DR   eggNOG; COG5032; -.
DR   GeneTree; ENSGT00620000087742; -.
DR   HOVERGEN; HBG052721; -.
DR   InParanoid; P42336; -.
DR   KO; K00922; -.
DR   OMA; AFAVRCL; -.
DR   OrthoDB; EOG45TCMC; -.
DR   PhylomeDB; P42336; -.
DR   BioCyc; MetaCyc:ENSG00000121879-MONOMER; -.
DR   BRENDA; 2.7.1.137; 2681.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; angiopoietinreceptor_pathway; Angiopoietin receptor Tie2-mediated signaling.
DR   Pathway_Interaction_DB; arf6cyclingpathway; Arf6 signaling events.
DR   Pathway_Interaction_DB; nfkappabatypicalpathway; Atypical NF-kappaB pathway.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epha2_fwdpathway; EPHA2 forward signaling.
DR   Pathway_Interaction_DB; ephbfwdpathway; EPHB forward signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; il1pathway; IL1-mediated signaling events.
DR   Pathway_Interaction_DB; il2_pi3kpathway; IL2 signaling events mediated by PI3K.
DR   Pathway_Interaction_DB; il2_stat5pathway; IL2 signaling events mediated by STAT5.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; il23pathway; IL23-mediated signaling events.
DR   Pathway_Interaction_DB; il4_2pathway; IL4-mediated signaling events.
DR   Pathway_Interaction_DB; il6_7pathway; IL6-mediated signaling events.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; mtor_4pathway; mTOR signaling pathway.
DR   Pathway_Interaction_DB; trkrpathway; Neurotrophic factor-mediated Trk receptor signaling.
DR   Pathway_Interaction_DB; avb3_opn_pathway; Osteopontin-mediated events.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; a4b1_paxdep_pathway; Paxillin-dependent events mediated by a4b1.
DR   Pathway_Interaction_DB; a4b1_paxindep_pathway; Paxillin-independent events mediated by a4b1 and a4b7.
DR   Pathway_Interaction_DB; pdgfrapathway; PDGFR-alpha signaling pathway.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; er_nongenomic_pathway; Plasma membrane estrogen receptor signaling.
DR   Pathway_Interaction_DB; reelinpathway; Reelin signaling pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; hedgehog_2pathway; Signaling events mediated by the Hedgehog family.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; ret_pathway; Signaling events regulated by Ret tyrosine kinase.
DR   Pathway_Interaction_DB; trail_pathway; TRAIL signaling pathway.
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Pathway_Interaction_DB; vegfr1_pathway; VEGFR1 specific signals.
DR   Pathway_Interaction_DB; lymphangiogenesis_pathway; VEGFR3 signaling in lymphatic endothelium.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111155; Cell-Cell communication.
DR   Reactome; REACT_116125; Disease.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Immune System.
DR   BindingDB; P42336; -.
DR   NextBio; 20442; -.
DR   ArrayExpress; P42336; -.
DR   Bgee; P42336; -.
DR   CleanEx; HS_PIK3CA; -.
DR   Genevestigator; P42336; -.
DR   GermOnline; ENSG00000121879; Homo sapiens.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0060048; P:cardiac muscle contraction; TAS:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; TAS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038028; P:insulin receptor signaling pathway via phosphatidylinositol 3-kinase cascade; TAS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0048011; P:nerve growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_Ca-dep.
DR   InterPro; IPR008973; C2_Ca/lipid-bd_dom_CaLB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR002420; PI3K_C2.
DR   InterPro; IPR003113; PI3K_p85-bd.
DR   InterPro; IPR000341; PI3K_ras-bd.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001263; PInositide-3_kin_accessory_dom.
DR   Gene3D; G3DSA:1.10.1070.11; PI3/4_kinase_cat; 1.
DR   Gene3D; G3DSA:1.25.40.70; PI3Ka; 1.
DR   PANTHER; PTHR10048; PI_Kinase; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM-type_fold; 1.
DR   SUPFAM; SSF49562; C2_CaLB; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50004; C2; FALSE_NEG.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51547; PI3K_C2; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Complete proteome;
KW   Disease mutation; Kinase; Nucleotide-binding; Polymorphism;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1   1068       Phosphatidylinositol-4,5-bisphosphate 3-
FT                                kinase catalytic subunit alpha isoform.
FT                                /FTId=PRO_0000088785.
FT   DOMAIN       16    105       PI3K-ABD.
FT   DOMAIN      187    289       PI3K-RBD.
FT   DOMAIN      330    487       C2 PI3K-type.
FT   DOMAIN      517    694       PIK helical.
FT   DOMAIN      797   1068       PI3K/PI4K.
FT   VARIANT      38     38       R -> H (in cancer; shows an increase in
FT                                lipid kinase activity; may disrupt the
FT                                interaction between the PI3K-ABD domain
FT                                and the N-terminal lobe of PI3K/PI4K
FT                                kinase domain possibly affecting the
FT                                conformation of the kinase domain).
FT                                /FTId=VAR_026166.
FT   VARIANT      43     43       I -> V (in dbSNP:rs1051399).
FT                                /FTId=VAR_042942.
FT   VARIANT      88     88       R -> Q (in cancer; may disrupt the
FT                                interaction between the PI3K-ABD domain
FT                                and the N-terminal lobe of PI3K/PI4K
FT                                kinase domain possibly affecting the
FT                                conformation of the kinase domain).
FT                                /FTId=VAR_026167.
FT   VARIANT     106    106       G -> V (in cancer; shows an increase in
FT                                lipid kinase activity).
FT                                /FTId=VAR_026168.
FT   VARIANT     332    332       S -> R (in dbSNP:rs1051407).
FT                                /FTId=VAR_042943.
FT   VARIANT     343    343       Y -> C (in cancer).
FT                                /FTId=VAR_026169.
FT   VARIANT     391    391       I -> M (in dbSNP:rs3729680).
FT                                /FTId=VAR_026170.
FT   VARIANT     420    420       C -> R (in cancer; shows an increase in
FT                                lipid kinase activity; may increase the
FT                                affinity for lipid membranes).
FT                                /FTId=VAR_026171.
FT   VARIANT     453    453       E -> Q (in cancer; shows an increase in
FT                                lipid kinase activity; may disrupt the
FT                                interaction of the C2 PI3K-type domain
FT                                with the iSH2 region of the p85
FT                                regulatory subunit).
FT                                /FTId=VAR_026172.
FT   VARIANT     542    542       E -> K (in KERSEB; shows an increase in
FT                                lipid kinase activity; oncogenic in vivo;
FT                                occurs in the interface between the PI3K
FT                                helical domain and the nSH2 (N-terminal
FT                                SH2) region of the p85 regulatory subunit
FT                                and may reduce the inhibitory effect of
FT                                p85; requires interaction with RAS to
FT                                induce cellular transformation).
FT                                /FTId=VAR_026173.
FT   VARIANT     542    542       E -> Q (in cancer).
FT                                /FTId=VAR_026174.
FT   VARIANT     542    542       E -> V (in cancer).
FT                                /FTId=VAR_026175.
FT   VARIANT     545    545       E -> A (in cancer).
FT                                /FTId=VAR_026176.
FT   VARIANT     545    545       E -> G (in KERSEB).
FT                                /FTId=VAR_026177.
FT   VARIANT     545    545       E -> K (in KERSEB; shows an increase in
FT                                lipid kinase activity; oncogenic in vivo;
FT                                occurs in the interface between the PI3K
FT                                helical domain and the nSH2 (N-terminal
FT                                SH2) region of the p85 regulatory subunit
FT                                and may reduce the inhibitory effect of
FT                                p85; requires interaction with RAS to
FT                                induce cellular transformation; enhances
FT                                invadopodia-mediated extracellular matrix
FT                                degradation and invasion in breast cancer
FT                                cells).
FT                                /FTId=VAR_026178.
FT   VARIANT     546    546       Q -> E (in cancer).
FT                                /FTId=VAR_026179.
FT   VARIANT     546    546       Q -> K (in cancer).
FT                                /FTId=VAR_026180.
FT   VARIANT     546    546       Q -> P (in cancer).
FT                                /FTId=VAR_026181.
FT   VARIANT     546    546       Q -> R (in cancer).
FT                                /FTId=VAR_026182.
FT   VARIANT    1007   1007       G -> R (in cancer).
FT                                /FTId=VAR_026183.
FT   VARIANT    1021   1021       Y -> C (in cancer).
FT                                /FTId=VAR_026184.
FT   VARIANT    1021   1021       Y -> H (in cancer).
FT                                /FTId=VAR_026185.
FT   VARIANT    1021   1021       Y -> N (in cancer).
FT                                /FTId=VAR_026186.
FT   VARIANT    1023   1023       R -> Q (in cancer).
FT                                /FTId=VAR_026187.
FT   VARIANT    1025   1025       T -> N (in cancer).
FT                                /FTId=VAR_026188.
FT   VARIANT    1035   1035       A -> V (in cancer).
FT                                /FTId=VAR_026189.
FT   VARIANT    1043   1043       M -> I (in cancer; shows an increase in
FT                                lipid kinase activity).
FT                                /FTId=VAR_026190.
FT   VARIANT    1047   1047       H -> L (in cancer).
FT                                /FTId=VAR_026191.
FT   VARIANT    1047   1047       H -> R (in KERSEB; shows an increase in
FT                                lipid kinase activity; oncogenic in vivo;
FT                                requires binding to p85 regulatory
FT                                subunit to induce cellular transformation
FT                                but not interaction with RAS; may mimic
FT                                the conformatitonal change triggered by
FT                                the interaction with RAS; enhances
FT                                invadopodia-mediated extracellular matrix
FT                                degradation and invasion in breast cancer
FT                                cells; increases lipid kinase activity;
FT                                may alter the interaction of the PI3K/
FT                                PI4K kinase domain with the cell
FT                                membrane).
FT                                /FTId=VAR_026192.
FT   VARIANT    1047   1047       H -> Y (in cancer).
FT                                /FTId=VAR_026193.
FT   VARIANT    1050   1050       G -> D (in cancer).
FT                                /FTId=VAR_026194.
FT   VARIANT    1052   1052       T -> K (in cancer).
FT                                /FTId=VAR_026195.
FT   VARIANT    1065   1065       H -> L (in cancer).
FT                                /FTId=VAR_026196.
FT   VARIANT    1065   1065       H -> Y (in cancer).
FT                                /FTId=VAR_026197.
FT   CONFLICT    170    170       N -> H (in Ref. 1; CAA82333).
FT   CONFLICT    187    187       K -> R (in Ref. 1; CAA82333).
FT   CONFLICT    286    287       ML -> KM (in Ref. 1; CAA82333).
FT   CONFLICT    346    346       V -> L (in Ref. 1; CAA82333).
FT   CONFLICT    723    723       K -> R (in Ref. 1; CAA82333).
FT   CONFLICT    751    751       F -> L (in Ref. 1; CAA82333).
FT   CONFLICT    767    767       E -> K (in Ref. 1; CAA82333).
FT   STRAND       13     15
FT   STRAND       18     25
FT   STRAND       31     37
FT   HELIX        42     52
FT   HELIX        53     55
FT   STRAND       56     58
FT   HELIX        59     61
FT   HELIX        65     67
FT   STRAND       69     74
FT   TURN         75     77
FT   STRAND       78     82
FT   HELIX        89     91
FT   STRAND       95    102
FT   HELIX       109    113
FT   HELIX       114    117
FT   HELIX       118    121
FT   HELIX       134    142
FT   HELIX       144    155
FT   TURN        156    159
FT   HELIX       160    165
FT   TURN        179    181
FT   HELIX       182    185
FT   STRAND      187    198
FT   TURN        199    202
FT   STRAND      203    212
FT   HELIX       217    229
FT   HELIX       236    240
FT   HELIX       247    249
FT   STRAND      250    257
FT   HELIX       267    269
FT   HELIX       271    279
FT   STRAND      284    289
FT   HELIX       290    294
FT   STRAND      332    341
FT   STRAND      357    364
FT   STRAND      377    380
FT   STRAND      382    393
FT   STRAND      401    405
FT   STRAND      425    430
FT   STRAND      439    444
FT   STRAND      453    455
FT   STRAND      458    460
FT   STRAND      468    470
FT   STRAND      472    477
FT   HELIX       488    492
FT   HELIX       495    498
FT   HELIX       539    541
FT   HELIX       545    553
FT   HELIX       555    558
FT   HELIX       562    564
FT   HELIX       565    570
FT   HELIX       577    588
FT   HELIX       597    602
FT   HELIX       609    622
FT   HELIX       625    630
FT   HELIX       632    638
FT   HELIX       639    641
FT   STRAND      643    646
FT   HELIX       648    657
FT   HELIX       661    672
FT   TURN        673    676
FT   HELIX       678    694
FT   HELIX       698    720
FT   HELIX       728    738
FT   HELIX       742    747
FT   STRAND      750    753
FT   STRAND      756    761
FT   STRAND      774    776
FT   STRAND      779    783
FT   TURN        791    794
FT   STRAND      797    805
FT   HELIX       808    826
FT   STRAND      838    842
FT   STRAND      845    849
FT   STRAND      852    856
FT   HELIX       857    862
FT   STRAND      867    869
FT   HELIX       871    873
FT   TURN        876    878
FT   HELIX       879    882
FT   TURN        886    888
FT   HELIX       889    911
FT   STRAND      920    924
FT   STRAND      929    931
FT   HELIX       958    963
FT   HELIX       975    993
FT   HELIX       995   1003
FT   TURN       1004   1007
FT   STRAND     1015   1018
FT   HELIX      1020   1025
FT   HELIX      1032   1047
SQ   SEQUENCE   1068 AA;  124284 MW;  041487231A9A1207 CRC64;
     MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLITIKHELF KEARKYPLHQ
     LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFA
     IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH
     IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK
     LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPMD
     CFTMPSYSRR ISTATPYMNG ETSTKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI
     YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC
     PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF
     SSVVKFPDMS VIEEHANWSV SREAGFSYSH AGLSNRLARD NELRENDKEQ LKAISTRDPL
     SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME
     LLDCNYPDPM VRGFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN
     QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK
     QEKKDETQKV QMKFLVEQMR RPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW
     LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS
     IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS
     CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF
     LIVISKGAQE CTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA
     YIRKTLALDK TEQEALEYFM KQMNDAHHGG WTTKMDWIFH TIKQHALN
//
